Milligan Michael Lee 4

Accession 0000950170-25-022325

CIK 0001885522other

View on SEC.gov Company Profile

Filed

Feb 17, 7:00 PM ET

Accepted

Feb 18, 4:30 PM ET

Size

24.5 KB

Accession

0000950170-25-022325

Insider Transaction Report

Form 4

Period: 2025-02-13

Neumora Therapeutics, Inc.NMRA

Milligan Michael Lee

See Remarks

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−38,234→ 0 total
Exercise: $6.51Exp: 2033-02-17→ Common Stock (38,234 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−28,675→ 0 total
Exercise: $6.36Exp: 2033-06-23→ Common Stock (28,675 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−41,250→ 0 total
Exercise: $18.07Exp: 2034-02-14→ Common Stock (41,250 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+38,234→ 38,234 total
Exercise: $1.69Exp: 2033-02-17→ Common Stock (38,234 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+400,000→ 400,000 total
Exercise: $1.69Exp: 2035-02-13→ Common Stock (400,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−85,391→ 0 total
Exercise: $4.63Exp: 2032-01-27→ Common Stock (85,391 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+85,391→ 85,391 total
Exercise: $1.69Exp: 2032-01-27→ Common Stock (85,391 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+28,675→ 28,675 total
Exercise: $1.69Exp: 2033-06-23→ Common Stock (28,675 underlying)
Award
Stock Option (Right to Buy)
2025-02-13+41,250→ 41,250 total
Exercise: $1.69Exp: 2034-02-14→ Common Stock (41,250 underlying)

Footnotes (7)

[F1]25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F2]25% of the shares subject to the option vest on the first anniversary measured from December 20, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F3]On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged.
[F4]25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F5]25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F6]25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
[F7]Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Neumora Therapeutics, Inc.

CIK 0001885522

→

Entity typeother

Related Parties

filerCIK 0001993953

Filing Metadata

Form type: 4
Filed: Feb 17, 7:00 PM ET
Accepted: Feb 18, 4:30 PM ET
Size: 24.5 KB

View on SEC.gov